Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Nautilus Biotechnology Q4 2023 GAAP EPS $(0.14) Beats $(0.15) Estimate

Author: Benzinga Newsdesk | February 28, 2024 08:10am
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 27.27 percent decrease over losses of $(0.11) per share from the same period last year.

Posted In: NAUT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist